Exhibit 99.2 Corporate Presentation NASDAQ: DCTH January 9, 2026 B Delcath Corporate Summary HEPZATO/CHEMOSAT Commercial Opportunity • 1Q 2024 HEPZATO (drug/device) US launch for mUM*, • Ultra orphan pricing with J-Code CHEMOSAT (device only) in EU • Focused call points • Included in NCCN Guidelines • US mUM TAM ~$500M • First and only FDA approved whole-liver directed therapy • 4Q 2025 Preliminary Total Revenue of$20.7M; Full Year Preliminary Total Revenue of $85.2M** Strong Financial Position** • Prelimi ...